Supreme Court Roundup Ruling Could Reshape Monsanto Cancer Lawsuits

The U.S. Supreme Court heard arguments on Monday in a pivotal case that could determine the future of tens of thousands of lawsuits against Bayer, the current owner of Monsanto, over its widely used herbicide Roundup. At issue is whether states have the authority to require warning labels on products like Roundup indicating a potential cancer risk, even when federal regulators have not mandated such labels. The outcome could reshape legal accountability for pesticide manufacturers and influence how consumers are warned about potential health hazards associated with chemical products.

Case Origins: A St. Louis Jury’s Verdict

The case before the Supreme Court, Monsanto v. Durrell, stems from a 2023 jury verdict in St. Louis, Missouri. John Durrell, a St. Louis resident, was awarded $1.25 million after a jury found that Roundup’s labeling failed to adequately warn users about the product’s cancer risks. Durrell’s lawsuit argued that prolonged exposure to Roundup, which contains the active ingredient glyphosate, contributed to his illness. Monsanto and Bayer have consistently disputed claims that glyphosate causes cancer, citing regulatory approvals and scientific studies that support its safety when used as directed.

The St. Louis jury’s decision marked one of several high-profile verdicts against Monsanto in recent years. Nearly 100,000 lawsuits have been filed by individuals alleging that Roundup exposure led to cancer, particularly non-Hodgkin lymphoma. While Bayer has settled many of these cases—reportedly paying out billions of dollars—thousands remain unresolved. The Supreme Court’s ruling could either uphold the ability of states to impose stricter labeling requirements or shield pesticide manufacturers from such lawsuits by deferring to federal regulatory oversight.

Federal Preemption: The Core Legal Question

The central legal question in Monsanto v. Durrell revolves around the doctrine of federal preemption. Bayer and its supporters argue that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) prevents states from imposing labeling requirements that differ from those approved by the Environmental Protection Agency (EPA). The EPA has repeatedly stated that glyphosate is not likely to cause cancer when used according to label instructions, and Bayer contends that allowing state-level lawsuits undermines the federal regulatory framework.

During Monday’s oral arguments, Paul Clement, an attorney representing Bayer, emphasized this point. The EPA regulation and the government’s brief here makes crystal clear that a registrant cannot change the safety warnings on a pesticide label without approval of the agency, Clement stated. He argued that permitting states to require additional warnings would create a patchwork of regulations, complicating compliance for manufacturers and potentially confusing consumers.

The Trump administration’s Department of Justice sided with Bayer in the case, with Deputy Solicitor General Sarah Harris arguing that EPA registers pesticides only if EPA approves their labels as adequate to protect health. Federal law then requires manufacturers to keep using that label. Manufacturers must apply to amend registration to change the label. This position aligns with Bayer’s argument that federal law should preempt state-level failure-to-warn claims.

Public Health Advocates Push Back

Public health and environmental advocacy groups have countered that federal preemption would leave consumers and workers without recourse if pesticide manufacturers fail to update labels in light of new scientific evidence. Earthjustice, a nonprofit environmental law organization, filed an amicus brief in the case, arguing that state lawsuits play a critical role in holding companies accountable when federal regulations lag behind emerging health risks.

Patti Goldman, a senior attorney at Earthjustice, noted during Monday’s arguments that Questions from the Justices recognized that the Environmental Protection Agency approves pesticide labels based on the evidence before the agency at a single moment in time, but that evidence can become outdated as real-world exposure grows and scientific studies document resulting harms. Goldman emphasized that federal law requires manufacturers to update labels to reflect new safety information, and state failure-to-warn claims reinforce this obligation while providing a pathway for affected individuals to seek compensation.

The Supreme Court previously addressed a similar issue in 2005 in Bates v. Dow Agrosciences LLC, ruling that individuals could pursue state law claims alleging inadequate pesticide warnings. However, Bayer and its supporters argue that the current case presents a different legal question—whether states can impose labeling requirements that go beyond federal standards, rather than merely allowing lawsuits based on existing labels.

Broader Implications for Pesticide Regulation

The Supreme Court’s decision in Monsanto v. Durrell could have far-reaching consequences for pesticide regulation and corporate accountability. If the Court sides with Bayer, it could effectively shield pesticide manufacturers from state-level lawsuits, limiting the ability of individuals to seek damages for health issues linked to chemical exposure. Such a ruling could also remove incentives for companies to proactively update labels in response to new scientific findings, potentially delaying warnings about emerging risks.

Conversely, a ruling in favor of Durrell and the state of Missouri could reinforce the role of state courts in addressing gaps in federal oversight. It could also encourage manufacturers to adopt more precautionary labeling practices to avoid litigation. The case has drawn attention from agricultural workers, environmental groups, and public health advocates, all of whom have a stake in how pesticide risks are communicated to the public.

Bayer has already taken steps to reduce its legal exposure related to Roundup. In 2021, the company announced that it would stop selling glyphosate-based Roundup products for residential use in the U.S., though it continues to market the herbicide for agricultural purposes. The company has also set aside billions of dollars to address existing and future Roundup-related claims, signaling the high stakes of the Supreme Court’s decision.

Scientific Debate Over Glyphosate’s Safety

The controversy over Roundup’s safety centers on glyphosate, the herbicide’s active ingredient. Glyphosate has been the subject of extensive scientific scrutiny, with conflicting conclusions about its potential health risks. The EPA has maintained that glyphosate is not likely to be carcinogenic to humans when used as directed, citing decades of regulatory reviews and scientific studies. However, other organizations, including the International Agency for Research on Cancer (IARC), a branch of the World Health Organization, classified glyphosate as probably carcinogenic to humans in 2015, based on limited evidence of cancer in humans and sufficient evidence in animal studies.

The discrepancy between these assessments has fueled ongoing debate among scientists, regulators, and public health experts. Critics of glyphosate argue that the EPA’s evaluations have relied heavily on industry-funded studies and have not adequately accounted for real-world exposure scenarios, such as long-term use by agricultural workers. Proponents of glyphosate, including Bayer and many farmers, contend that the herbicide is a critical tool for modern agriculture and that its risks are manageable with proper use.

The Supreme Court’s decision is unlikely to resolve the scientific debate over glyphosate’s safety. However, it could influence how such debates are addressed in the future, particularly in cases where new evidence emerges after a product has received regulatory approval. If the Court rules that federal preemption bars state-level lawsuits, it could limit the ability of individuals to challenge the adequacy of pesticide warnings based on evolving scientific understanding.

What Comes Next

The Supreme Court is expected to issue its ruling in Monsanto v. Durrell by the end of its current term in June 2026. The decision will be closely watched by legal experts, public health advocates, and the agricultural industry, all of whom have a vested interest in its outcome. For the tens of thousands of plaintiffs with pending Roundup lawsuits, the ruling could determine whether they have a viable path to seek compensation for their alleged injuries.

Regardless of the outcome, the case highlights broader questions about the balance between federal regulation and state-level accountability in protecting public health. It also underscores the challenges of regulating chemicals in an era of rapidly evolving scientific knowledge and growing public awareness of environmental health risks. As the legal battle over Roundup continues, the Supreme Court’s decision will shape not only the future of pesticide litigation but also the broader landscape of corporate responsibility and consumer safety.